AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26155923
Drug: Short acting
RxNorm normalized name: Prolixin (short acting injection) 2.5 MG/ML Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short acting bronchodilators (Proventil HFA)
Trial: 26155923
Drug: Both inhalers
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both inhalers (ICS and bronchodilators)
Trial: 19808136
Drug: Gabapentin enacarbil
RxNorm normalized name: Gabapentin Enacarbil
DrugBank: Gabapentin enacarbil (DB08872)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin enacarbil 600-mg extended-release tablets at doses of 2400, 3600, 4800, or 6000 mg
Trial: 15829527
Drug: Donepezil (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil (10 mg daily)
Trial: 11345514
Drug: Cognitive orientation
RxNorm normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive orientation to daily occupational performance (CO-OP)
Trial: 9013720
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with carbetamide and caffeine to induce autotetraploid cells
Trial: 30744491
Drug: Telerehabilitation-based motor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telerehabilitation-based motor imagery training (Tele-MIT) twice a week for 8 weeks
Trial: 30744491
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (wait-list group without any additional specific treatment)
Trial: 21355143
Drug: Acupuncture applied
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acupuncture applied to non-acupoint spots with shallow needling technique and Fluoxetine taken orally.
Trial: 16750465
Drug: Amlodipine orotate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine orotate (5 mg, doubled to 10 mg QD if SiDBP >= 90 mm Hg after 4 weeks)
Trial: 16750465
Drug: Amlodipine besylate
RxNorm normalized name: Amlodipine Besylate
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine besylate (5 mg, doubled to 10 mg QD if SiDBP >= 90 mm Hg after 4 weeks)
Trial: 9158883
Drug: 2.4 mg
RxNorm normalized name: pectin 2.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.4 mg kg‐1 dolasetron mesylate (1.8 mg kg‐1 dolasetron base) by intravenous administration
Trial: 9158883
Drug: 2.4 mg
RxNorm normalized name: pectin 2.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.4 mg kg‐1 dolasetron mesylate (1.8 mg kg‐1 dolasetron base) by oral administration
Trial: 3619423
Drug: Both intravenous
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both intravenous and oral administration
Trial: 8214547
Drug: Intramuscular pethidine
RxNorm normalized name: pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular pethidine 75 mg
Trial: 2443151
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy combined with bleomycin
Trial: 2443151
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy combined with a retinoid
Trial: 26315564
Drug: Osteotome sinus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteotome sinus floor elevation (OSFE) with β‐TCP and DBB combination
Trial: 25012498
Drug: Renin-angiotensin system
RxNorm normalized name: Renin-angiotensin system inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renin-angiotensin system inhibition (RASI) with angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB)
Trial: 19776651
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment based on conventional laboratory parameters
Trial: 10787068
Drug: Dextromethorphan 10
RxNorm normalized name: DEXTROMETHORPHAN 10MG CHEWABLE TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextromethorphan 10 mg IM
Trial: 10787068
Drug: Dextromethorphan 20
RxNorm normalized name: dextromethorphan 20 mg/15 mL oral syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextromethorphan 20 mg IM
Trial: 10787068
Drug: Dextromethorphan 40
RxNorm normalized name: guaifenesin/dextromethorphan 400 mg-20 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextromethorphan 40 mg IM
Trial: 10787068
Drug: Control (Chlorpheniramine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Chlorpheniramine maleate 20 mg IM)
Trial: 6148960
Drug: xamoterol 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: xamoterol 0.1 mg/kg
Trial: 30656171
Drug: Gabapentin 300
RxNorm normalized name: gabapentin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin 300 mg per night and nocturnal splint
Trial: 30656171
Drug: Gabapentin 300
RxNorm normalized name: gabapentin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin 300 mg per night, exercises, and nocturnal splint
Trial: 25305703
Drug: Eicosapentaenoic acid
RxNorm normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eicosapentaenoic acid (EPA) 1800 mg/day initiated within 24 hours after PCI
Trial: 20579863
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg Pycnogenol a day
Trial: 20579863
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Pycnogenol and elastic stockings
Trial: 16534182
Drug: Pitavastatin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pitavastatin (1 mg/day, n = 15)
Trial: 1854026
Drug: 0.5% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% bupivacaine with 5 micrograms/mL epinephrine
Trial: 6337670
Drug: Anal dilator
RxNorm normalized name: Mephitis mephitis anal gland fluid preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anal dilator (no. 2) twice daily for 3 weeks
Trial: 26852743
Drug: Medical management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical management (ongoing therapy)
Trial: 26852743
Drug: Medical management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical management with treatment crossover to endoscopic sinus surgery (ESS)
Trial: 18653310
Drug: Individual cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual cognitive behavior therapy (CBT)
Trial: 22001151
Drug: Topical ciclosporin
RxNorm normalized name: ciclosporin
DrugBank: Cyclosporine (DB00091)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topical ciclosporin A (CsA) 2%
Trial: 7871449
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg ciprofloxacin
Trial: 3764628
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg ciprofloxacin
Trial: 27722222
Drug: Immediate-delayed implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-delayed implants (6 weeks)
Trial: 27722222
Drug: Delayed implants
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed implants (4 months)
Trial: 18503141
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg tadalafil + 5 mg nitrendipine
Trial: 12702127
Drug: Trizivir (abacavir-lamivudine-zidovudine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trizivir (abacavir-lamivudine-zidovudine combination tablet) administered twice daily
Trial: 12702127
Drug: Continued treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued treatment (two nucleoside reverse transcriptase inhibitors plus a protease inhibitor or a nonnucleoside reverse transcriptase inhibitor or three nucleoside reverse transcriptase inhibitors)
Trial: 12702127
Drug: Trizivir (abacavir-lamivudine-zidovudine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trizivir (abacavir-lamivudine-zidovudine combination tablet)
Trial: 10752915
Drug: Flunisolide administered
RxNorm normalized name: Flunisolide
DrugBank: Flunisolide acetate (DB14662)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flunisolide administered via AeroChamber, 750 microg (3 puffs), twice daily
Trial: 10752915
Drug: Budesonide administered
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide administered via Turbuhaler, 600 microg (3 puffs), twice daily
Trial: 9373479
Drug: Topical levobunolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical levobunolol HCl 0.5% (LEV)
Trial: 9373479
Drug: Topical levobunolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical levobunolol HCl 0.5% (LEV) vs Artificial tears (TEAR)
Trial: 27943153
Drug: Sorafenib 200
RxNorm normalized name: sorafenib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib 200 mg BID days 1-28 plus Bevacizumab 2.5 mg/kg every other week (MTD)
Trial: 27943153
Drug: Sorafenib 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib 400 mg BID (phase I)
Trial: 27943153
Drug: Sorafenib 200
RxNorm normalized name: sorafenib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib 200 mg BID plus Bevacizumab 2.5 mg/kg (phase II)
Trial: 29798325
Drug: Yanhouqing buccal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yanhouqing buccal tablets (high dose)
Trial: 29798325
Drug: Yanhouqing buccal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yanhouqing buccal tablets (low dose)
Trial: 29798325
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (Yanhouqing buccal tablets and placebo)
Trial: 24619016
Drug: Famotidine 40
RxNorm normalized name: famotidine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine 40 mg (80 mg/day) administered twice daily (4 and 3 hours prior to each radiotherapy fraction)
Trial: 24619016
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered twice daily (4 and 3 hours prior to each radiotherapy fraction)
Trial: 19741581
Drug: Simvastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (20 mg/day, group A, N. 22)
Trial: 14633533
Drug: Esmolol 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol 50 mg and nicardipine 1 mg, followed by an esmolol infusion 5 microg x kg(‐1) x min(‐1)
Trial: 14633533
Drug: Esmolol 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol 50 mg, followed by an esmolol infusion 5 microg x kg(‐1) x min(‐1)
Trial: 14633533
Drug: Esmolol infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol infusion as an adjunct to desflurane
Trial: 14633533
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 5 mL and 1 mL, followed by a saline infusion at a rate of 0.005 mL x kg(‐1) x min(‐1)
Trial: 10540300
Drug: Regimen I:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen I: 300 mg dihydroartemisinin + 750 mg mefloquine concurrently
Trial: 10540300
Drug: Regimen II:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen II: 300 mg dihydroartemisinin + 750 mg mefloquine 24 h later
Trial: 10540300
Drug: Regimen III:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen III: 300 mg dihydroartemisinin + 750 mg mefloquine at 24 h and 500 mg at 30 h
Trial: 10540300
Drug: Regimen IV:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen IV: 300 mg dihydroartemisinin + 750 mg mefloquine at 0 h and 500 mg at 24 h
Trial: 10540300
Drug: High-dose mefloquine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose mefloquine regimens (III and IV)
Trial: 10540300
Drug: Patients who
RxNorm normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who vomited within the first hour of mefloquine administration
Trial: 7037162
Drug: Cyclophosphamide 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide 600 mg/m2 IV plus DTIC 600 mg/m2 IV day 1 (CD)
Trial: 7037162
Drug: Cyclophosphamide 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide 400 mg/m2 IV, DTIC 400 mg/m2 IV, and piperazinedione 4 mg/m2 IV on day 1 (PCD)
Trial: 7037162
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment programs (CD and PCD)
Trial: 31665314
Drug: Denosumab 60
RxNorm normalized name: denosumab 60 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denosumab 60 mg every 6 months in year 1
Trial: 31665314
Drug: Alendronate 70
RxNorm normalized name: ALENDRONATE 70MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate 70 mg once-weekly in year 2
Trial: 23812892
Drug: Culturally adapted
RxNorm normalized name: casein, emmental cultured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culturally adapted cognitive-behavioral therapy for adherence and depression with an alarmed pillbox
Trial: 10443750
Drug: Insulin (0.035
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin (0.035 IU/kg i.v.)
Trial: 8688258
Drug: Neostigmine 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine 0.05 mg kg‐1 and glycopyrronium 0.01 mg kg‐1
Trial: 8688258
Drug: No neuromuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No neuromuscular blockers
Trial: 6352035
Drug: Gentamicin-cefoxitin (G-C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin-cefoxitin (G-C)
Trial: 18085139
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of Lactein tablets, 1-2 tablets, 3 times daily for 4 weeks
Trial: 9165134
Drug: RT plus
RxNorm normalized name: Recort Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT plus 6 mg/m2 of cisplatin (CDPP)
Trial: 9165134
Drug: RT plus
RxNorm normalized name: Recort Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT plus 25 mg/m2 of carboplatin (CBDCA)
Trial: 24335056
Drug: G allele
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G allele of MTNR1B rs10830963
Trial: 24334573
Drug: rosuvastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosuvastatin (10 mg per day)
Trial: 24334573
Drug: simvastatin/ezetimibe (10/10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: simvastatin/ezetimibe (10/10 mg per day)
Trial: 16671429
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (S group)
Trial: 16671429
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (C group)
Trial: 8230497
Drug: Potassium citrate
RxNorm normalized name: Potassium Citrate
DrugBank: Potassium (DB14500)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Potassium citrate (30 to 60 mEq daily for 3 years)
Trial: 3764522
Drug: Single-dose parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose parenteral therapy
Trial: 3764522
Drug: Triple-dose parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple-dose parenteral therapy
Trial: 3764522
Drug: Parenteral and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral and lavage therapy
Trial: 3764522
Drug: Lavage therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lavage therapy alone
Trial: 18948425
Drug: Oral itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral itraconazole (200 mg twice daily)
Trial: 14988448
Drug: Dairy protein
RxNorm normalized name: Beano Dairy Defense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dairy protein diet (DP, 2400 mg Ca/d)
Trial: 14988448
Drug: Mixed protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed protein sources diet (MP, 500 mg Ca/d)
Trial: 31492652
Drug: Ozanimod 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozanimod 1.0 mg
Trial: 26879276
Drug: Ozanimod 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozanimod 0.5 mg
Trial: 27418639
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (LMWH) treatment
Trial: 25552364
Drug: CEF (dose-intense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEF (dose-intense cyclophosphamide, epirubicin, and flurouracil)
Trial: 25552364
Drug: EC/T (dose-dense,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EC/T (dose-dense, dose-intense epirubicin, cyclophosphamide, and paclitaxel)
Trial: 21610239
Drug: Oral prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral prednisone (60 mg/d for 14 days with a 5-day taper)
Trial: 21610239
Drug: Intratympanic methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intratympanic methylprednisolone (4 doses over 14 days of 40 mg/mL injected into the middle ear)
Trial: 19904567
Drug: PSE-enriched margarine
RxNorm normalized name: MARGARINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSE-enriched margarine (2.5 g/day of plant stanols)
Trial: 16739847
Drug: Blood-letting therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood-letting therapy combined with tapping Huatuo Jiaji (EX-B2) on the back by plum-blossom needle, once daily for 6 times (1 course)
Trial: 16739847
Drug: Routine acupuncture
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine acupuncture at points of the four limbs, once daily for 12 times (1 course)
Trial: 9612237
Drug: Sodium phenylbutyrate
RxNorm normalized name: Sodium Phenylbutyrate
DrugBank: Phenylbutyric acid (DB06819)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium phenylbutyrate (phi B) at a dose of 0.36 g.kg‐1.day‐1 for 24 hours
Trial: 31192682
Drug: PUFA Ω‐3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PUFA Ω‐3 (2.4 g/day; EPA 1.6 g and DHA 0.8 g)
Trial: 26304969
Drug: 3-month diabetes
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3-month diabetes self-management education (DSME) program followed by 12 months of weekly group sessions and supplementary telephone support delivered by peer leaders
Trial: 23100082
Drug: Ozone treatment
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozone treatment via major autohemotherapy (10 sessions)
Trial: 23100082
Drug: Betahistine (48
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betahistine (48 mg/day for 3 months)
Trial: 18484559
Drug: Moderate insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moderate insulin infusion (0.8 microU/kg/min)
Trial: 18484559
Drug: High insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High insulin infusion (1.6 microU/kg/min)
Trial: 18484559
Drug: Hypoglycemia (blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypoglycemia (blood glucose lowered to 2.5 mmol/l)
Trial: 14662282
Drug: FDG PET-guided
RxNorm normalized name: Pet-ema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDG PET-guided therapy
Trial: 11451177
Drug: HBV vaccination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBV vaccination (preS2/S, GenHevac B, Pasteur‐Mérieux), 20 microg, five intramuscular injections
Trial: 11451177
Drug: HBV vaccination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBV vaccination (S vaccine, Recombivax Merck & Co.), five intramuscular injections
Trial: 11451177
Drug: HBV vaccination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBV vaccination (any vaccine), five injections
Trial: 11451177
Drug: HBV vaccination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBV vaccination (any vaccine)
Trial: 7799770
Drug: 20 g.l‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g.l‐1 glucose solution
Trial: 7799770
Drug: 40 g.l‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 g.l‐1 glucose solution
Trial: 7799770
Drug: 60 g.l‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 g.l‐1 glucose solution
Trial: 29031889
Drug: Pressure garment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pressure garment therapy (PGT)
Trial: 23180114
Drug: Everolimus 10
RxNorm normalized name: everolimus 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus 10 mg once daily until disease progression or unacceptable toxicity
Trial: 25073663
Drug: peginterferon-β1a 125
RxNorm normalized name: Peginterferon Beta-1A
DrugBank: Peginterferon beta-1a (DB09122)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: peginterferon-β1a 125 µg via single-use autoinjector
Trial: 21983985
Drug: Dialysate with
RxNorm normalized name: Dialyvite 800 with Zinc Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialysate with low K (2 mmol/L), low Ca (1.25 mmol/L), high bicarbonate (34 mmol)
Trial: 21983985
Drug: Dialysate with
RxNorm normalized name: Dialyvite 800 with Zinc Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialysate with high K (3 mmol/L), high Ca (1.75 mmol/L), bicarbonate (30 mmol)
Trial: 19923061
Drug: Premarin (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Premarin (0.3 mg/day and 0.6 mg/day alternately, n=29)
Trial: 19923061
Drug: Kuntai capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kuntai capsule (4 g/day, n=28)